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Abstract 21 
Seventy two (54.5%) out of 132 fecal samples were positive for either extended 22 
spectrum beta-lactamases (ESBL) (51.5%), carbapenemase (1.5%) or cephamycinase 23 
(1.5%) producing Escherichia coli from a group of yellow–legged gulls in Barcelona, 24 
Spain. The isolation of two carbapenemase-producing E. coli strains is a matter of 25 
concern.  26 
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In the last decade, the number of bacterial pathogens presenting multidrug 41 
resistance to antibacterial agents has increased dramatically, becoming an emergent 42 
global concern and a major public health problem (1). The main cause behind the 43 
increasing rates of resistance can ultimately be found in the abuse and misuse of 44 
antibacterial agents, whether used in patients and livestock or released into the 45 
environment. Once antimicrobial resistant bacteria emerge, they can spread locally or 46 
globally. The main factors contributing to their spread at a global level comprise 47 
migrant birds, globalization of commercial food and international travelling.  48 
There have been several studies about the presence of resistant bacteria in gulls 49 
(2,3), to the extent of being considered as an indicator of environmental antibiotic 50 
resistance occurrence, as they are distributed almost all around the world (4). Meerburg 51 
et al (5) showed that gulls feces contain a greater average concentration of E. coli than 52 
other wild animals and according to Stedt et al (4), Spain is the country in Europe with 53 
the highest levels of gull E. coli isolates resistant to ≥1 antibiotic.  54 
The objective of this study was to investigate the prevalence of extended spectrum beta-55 
lactamases (ESBL) and/or carbapenemase-producing Enterobacteriaceae from fecal 56 
swabs obtained from a group of yellow–legged gulls (Larus michahellis) in Barcelona, 57 
Spain. 58 
The study was conducted from the beginning of May to late July 2014  in the 59 
city of Barcelona, including the breeding period of the yellow-legged gull in the city. 60 
The sampling program was part of the sanitary and epidemiological surveillance that is 61 
carried out by the Public Health Agency, Barcelona, institution responsible for the 62 
supervision and surveillance of the species. The sampling sites were chosen according 63 
to citizens’ reports regarding the species nesting on their terraces or high roofs of the 64 
city. Every gull chick from each nest found (Figure) was sampled, which amounts to 65 
132 samples in total. All samples were obtained from young specimens born in that 66 
same year, and all nests were independent from each other, since the urban structure of 67 
cities promotes isolated instead of colonial nesting. Fecal material was obtained by 68 
sampling the cloaca of gull chicks with sterile swabs. Each swab was individually 69 
preserved in Cary-Blair medium, at 2-8 ºC and analyzed within 24 h in the Laboratory 70 
of the Public Health Agency, Barcelona. 71 
The samples were plated on ESBL chromogenic agar (Biomérieux, France) and 72 
burgundy red colonies were selected, according to the manufacturer’s instructions. 73 
Colonies were further identified by mass spectrometry (MALDI-TOF) (Bruker 74 
Daltonics Inc., Bremen, Germany). Susceptibility to ampicillin, amoxicillin/clavulanic 75 
acid, cefuroxime, ceftriaxone, cefotaxime, meropenem, gentamicin, amikacin, nalidixic 76 
acid, and ciprofloxacin was determined by the disk diffusion method following the 77 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines 78 
and breakpoints (version 5.0, 2015; http://www.eucast.org). The double-disk diffusion 79 
technique was performed for phenotypic ESBL detection. The presence of 80 
carbapenemases was assessed with the modified Hodge test according to phenotypic 81 
susceptibility results. Characterization of ESBL and carbapenemases genes was 82 
performed by PCR followed by DNA sequencing (6) (ESBL: blaTEM, blaSHV, blaCTX-M 83 
genes; carbapenemases: blaKPC, blaOXA-48, blaVIM, blaIMP and blaNDM genes; 84 
cephamycinases: blaCMY, blaDHA, blaFOX, blaACC, blaEBC, blaMOX genes). Seventy two 85 
(54.5%) out of 132 fecal samples were positive for either ESBL (68/132, 51.5%), 86 
carbapenemase (2/132, 1.5%) or cephamycinase (2/132, 1.5%) producing Escherichia 87 
coli (Table 1), with SHV being the most prevalent the group (38/132, 28.8%). Forty-88 
five strains (62.5%) were resistant to quinolones, 22 (30.6%) to gentamicin and 9 89 
(12.5%) to amikacin. Rep-PCR showed a high genetic heterogeneity among the strains 90 
with up to 57 different clones, 15 of them containing two different isolates each (data 91 
not shown). Agglutination with antiserum O:25 was used to identify CTXM-15 92 
producing isolates belonging to the high risk clone O:25b-ST131, but all isolates were 93 
negative.  94 
Of note, two E. coli isolates co-carried both the blaKPC−2 and blaVIM genes for 95 
carbapenem resistance. Multilocus sequence typing (MLST) 96 
(http://mlst.warwick.ac.uk/mlst/dbs/Ecoli) and PCR-based phylogroup analysis (7) 97 
identified them as belonging to the ST1011 phylogroup E (strain 40) and ST354 98 
phylogroup F (strain 71), respectively, which have been previously reported in human 99 
strains (8,9).  The genetic transference of carbapenemase genes was tested by biparental 100 
mating experiments using E. coli J53 AziR as the recipient strain. Transconjugants were 101 
selected in Mueller-Hinton agar plates containing 100μg/mL of sodium azide and 102 
1μg/mL meropenem (Sigma Chemical Co., St Louis, MO). Successful conjugation was 103 
confirmed by specific PCR amplification. Table 2 shows the MICs determined by Etest 104 
of different antibiotics for the original and transconjugant strains with the corresponding 105 
carbapenemases harbored.  106 
Plasmid analysis by S1 nuclease–pulsed-field gel electrophoresis (PFGE) (6) and 107 
replicon typing (6) were then performed on both the original strains and transconjugants 108 
to determine the size of these plasmids and classify them within the incompatibility 109 
groups. Digoxigenin-labeled probes for the blaVIM and blaKPC genes were hybridized 110 
against blotted nylon membranes from the S1-PFGE gels. The blaKPC-2 gene was located 111 
in a plasmid size ca. 60 kb in strain 40 and in a plasmid of <50kb in strain 71, both 112 
being non-typeable plasmids. The genetic environment of the blaKPC-2 genes was 113 
determined by inverse PCR, leading to the identification of a ISKpn27-ΔTEM-blaKPC−2-114 
ISKpn6-korC genetic arrangement, which was similar to those previously described 115 
among different isolates of human origin from China and Taiwan (10,11). Further 116 
analysis based on Next Generation Sequencing is needed to describe additional 117 
elements of these plasmids for a more robust analysis.  118 
The blaVIM-1 gene was located in both strains in an In3103 class I integron, 119 
carried in a ca. 100kb plasmid belonging to the incompatibility group I1-Iγ. This 120 
integron also cointained an aminoglycoside 6'-N-acetyltransferase (aacA4) gene and a 121 
3'-(9)-O-adenylyltransferase (aadA1) gene. The presence of the blaVIM-1 gene within an 122 
In3103 class I integron was also described by at least one report in Spain, albeit in that 123 
case it was located in a non-typeable plasmid of ca. 60 kb and recovered from a human 124 
patient (12). 125 
Our data showed a higher percentage of resistant E. coli in gulls fecal samples 126 
compared with previous studies (13–15) but it also represents the first study reporting 127 
the coexistence of two carbapenemase genes in E.coli recovered from yellow-legged 128 
gulls. Although some OXA-48 producing E.coli could have been lost due to the 129 
methodology followed that was specifically designed to search for ESBL. The fact that 130 
carbapenem resistant isolates recovered from the fecal samples of gulls share the same 131 
sequence types and resistance modules as those recovered from human samples in 132 
different parts f the world highlights the potential role of migratory birds in the 133 
dissemination and spread of antibiotic resistance genes.   134 
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Figure. Location of sites where positive (green) and negative (red) samples were 208 
collected (Barcelona, Spain). 209 
Table 1. Distribution of β-lactamases. 210 
β-lactamase Nº of strains % 
SHV Group 38 52.8 
SHV-12 24 33.3 
SHV-12 + TEM-1 13 18 
SHV-2 1 1.4 
CTX-M group 30 41.6 
CTX-M-15 11 15.3 
CTX-M-15 + TEM-1 2 2.8 
CTX-M-1 1 1.4 
CTX-M-1 + TEM-1 5 6.9 
CTX-M-1 + TEM-84 1 1.4 
CTX-M-14 4 5.5 
CTX-M-14 + TEM-1 6 8.3 
VIM-1 + KPC-2 2 2.8 
CMY-2 2 2.8 
TOTAL 72 100 
 211 
Table 2. In vitro susceptibilities of original strains of E. coli and E. coli transconjugants expressing VIM-1 and/or KPC-2 (Etest, EUCAST). 212 
 MIC (μg/ml) 
 Original strains Transconjugants 
Antibiotics 
E. coli 40A 
(VIM-1/KPC-2) 
E. coli 71B 
(VIM-1/KPC-2) 
E. coli J53 C 
E. coli J53 40T3D 
(KPC-2) 
E. coli J53 40T5E 
(VIM-1/KPC-2) 
E. coli J53 71T1F 
(VIM-1) 
E. coli J53 71T3G 
(VIM-1/KPC-2) 
Cefoxitin >256 >256 2 8 256 256 64 
Cefotaxime 32 24 0.094 0.75 16 16 64 
Ceftazidime 256 96 0.125 1 64 64 96 
Imipenem 4 24 0.19 1.5 3 1 12 
Meropenem 4 32 0.023 0.75 0.5 0.25 8 
Ertapenem 6 12 0.008 0.38 0.38 0.64 4 
Aztreonam 16 128 0.064 12 16 0.25 256 
Ciprofloxacin >32 >32 0.064 0.047 0.064 0.064 0.064 
Gentamicin >32 >32 0.25 0.25 1 2 2 
Amikacin 3 3 1 1 1.5 1.5 1.5 
Tobramycin 16 12 0.125 0.125 3 3 3 
Colistin 0.25 0.125 0.125 0.25 0.125 0.19 0.25 
 213 
A E. coli strain 40 isolated from a yellow–legged gull. 214 
B E. coli strain 71 isolated from a yellow–legged gull. 215 
C Sodium azide-resistant E. coli J53 strain used as a recipient in the conjugation experiment. 216 
D E. coli transconjugant obtained from strains 40 and J53 that received only the blaKPC-2. 217 
E E. coli transconjugant obtained from strains 40 and J53 that received both the blaKPC-2 and the blaVIM-1. 218 
F E. coli transconjugant obtained from strains 71 and J53 that received only the blaVIM-1. 219 
G E. coli transconjugant obtained from strains 71 and J53 that received both the blaKPC-2 and the blaVIM-1. 220 
 221 

